Cardio Diagnostics (NASDAQ:CDIO) Stock Price Down 3.9%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) traded down 3.9% during mid-day trading on Wednesday . The company traded as low as $0.47 and last traded at $0.48. 128,888 shares traded hands during trading, a decline of 83% from the average session volume of 739,872 shares. The stock had previously closed at $0.50.

Wall Street Analysts Forecast Growth

Separately, Benchmark upped their target price on shares of Cardio Diagnostics from $1.35 to $2.00 and gave the stock a “speculative buy” rating in a report on Thursday, June 6th.

Cardio Diagnostics Price Performance

The firm has a 50 day moving average price of $0.59 and a 200 day moving average price of $1.19.

Hedge Funds Weigh In On Cardio Diagnostics

An institutional investor recently bought a new position in Cardio Diagnostics stock. Vontobel Holding Ltd. bought a new stake in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,000 shares of the company’s stock, valued at approximately $30,000. Vontobel Holding Ltd. owned about 0.06% of Cardio Diagnostics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.